<p>Xponance Inc. 在最近向證券交易委員會提交的 13F 文件中表示，在第四季度購買了 Guardant Health, Inc. (NASDAQ:GH - 免費報告) 的新頭寸。該公司購買了 8,534 股該公司的股票，價值約為 261,000 美元。</p>
<p>獲取 <strong>Guardant Health</strong> 警報：</p>
<ul>
<li>4 只醫療保健股票大幅上漲——還有更多上漲空間</li>
</ul>
<p>其他幾家對沖基金最近也對該公司的頭寸進行了調整。R Squared Ltd 在第四季度以約 26,000 美元的價格購買了 Guardant Health 的新頭寸。SBI Securities Co. Ltd. 在第四季度以約 43,000 美元的價格購買了 Guardant Health 的新頭寸。Kimelman &amp; Baird LLC 在第四季度以約 58,000 美元的價格購買了 Guardant Health 的新頭寸。Jones Financial Companies Lllp 在第四季度將其在 Guardant Health 的持股比例提高了 43.5%。Jones Financial Companies Lllp 目前擁有 2,696 股該公司的股票，價值 82,000 美元，此前在此期間又增持了 817 股。最後，Van ECK Associates Corp 在第四季度將其在 Guardant Health 的持股比例提高了 47.4%。Van ECK Associates Corp 目前擁有 2,887 股該公司的股票，價值 88,000 美元，此前在上個季度又增持了 929 股。92.60% 的股票由對沖基金和其他機構投資者持有。</p>
<h2>Guardant Health 價格表現</h2>
<p>Guardant Health 股票週五開盤價為 43.14 美元。該公司的市值為 53.2 億美元，市盈率為 -12.12，貝塔值為 1.50。Guardant Health, Inc. 的一年低點為 15.81 美元，一年高點為 50.89 美元。該公司的 50 日移動平均線為 44.66 美元，200 日移動平均線為 34.24 美元。</p>
<ul>
<li>解讀顛覆：深入瞭解 Cathie Wood 的最新投資</li>
</ul>
<p>Guardant Health (NASDAQ:GH - 獲取免費報告) 最近於 2 月 20 日星期四發佈了其財報。該公司報告本季度每股收益為（$0.90），低於市場共識預期的（$0.75）$0.15。該公司本季度的收入為 2.0181 億美元，而市場共識預期為 1.9250 億美元。Guardant Health 的股本回報率為 -19,157.20%，淨利潤率為 -59.05%。分析師平均預計 Guardant Health, Inc. 本財年的每股收益為 -2.9。</p>
<h2>華爾街分析師預測增長</h2>
<p>幾家券商對 GH 發表了評論。摩根大通將 Guardant Health 的目標價從 50.00 美元上調至 55.00 美元，並在 2 月 21 日的報告中給予該股票 “增持” 評級。摩根士丹利將 Guardant Health 的目標價從 42.00 美元上調至 52.00 美元，並在 3 月 6 日的研究報告中給予該股票 “增持” 評級。Canaccord Genuity Group 將 Guardant Health 的目標價從 42.00 美元上調至 60.00 美元，並在 2 月 24 日的研究報告中給予該公司 “買入” 評級。Stifel Nicolaus 將 Guardant Health 的目標價從 45.00 美元上調至 53.00 美元，並在 2 月 21 日的報告中給予該股票 “買入” 評級。最後，高盛集團將 Guardant Health 的目標價從 49.00 美元上調至 56.00 美元，並在 2 月 21 日的研究報告中給予該公司 “買入” 評級。20 位投資分析師對該股票給予了 “買入” 評級，根據 MarketBeat.com 的數據，Guardant Health 目前的平均評級為 “買入”，平均目標價為 48.95 美元。</p>
<ul>
<li>3 只快速增長的股票分析師預計價格翻倍</li>
</ul>
<p><strong>查看我們對 Guardant Health 的最新股票分析</strong></p>
<h2>Guardant Health 公司簡介</h2>
<p>（免費報告）</p>
<p>Guardant Health, Inc. 是一家精準腫瘤學公司，在美國和國際上提供血液和組織檢測、數據集和分析。該公司提供 Guardant360；Guardant360 LDT；Guardant360 CDx 測試；Guardant360 反應測試；Guardant360 TissueNext 測試；GuardantINFINITY 測試；GuardantConnect，一種為臨牀和生物製藥客户設計的集成軟件解決方案，旨在將接受檢測的患者與具有潛在相關臨牀研究的可操作性改變相連接；GuardantOMNI 測試用於晚期癌症；以及 GuardantINFORM，一種用於各種生物標誌物驅動癌症的腫瘤演變和治療耐藥性的計算機研究平台。</p>
<h2>精選故事</h2>
<ul>
<li>五隻我們更看好的股票，勝過 Guardant Health</li>
<li>比較和交易高市盈率股票</li>
<li>為什麼 Dollar Tree 的 Family Dollar 出售可能會引發復甦</li>
<li>股息王寶潔在財報後疲軟時值得買入</li>
<li>摩根大通：銀行業的 “英偉達” 有望獲得更多收益？</li>
<li>股票回購是什麼？投資者的全面指南</li>
<li>買入 Chewy 股票反轉？這是現在的時機</li>
</ul>
<p><strong>想看看其他對沖基金持有 GH 的股票嗎？</strong> 訪問 HoldingsChannel.com 獲取 Guardant Health, Inc. (NASDAQ:GH - 免費報告) 的最新 13F 文件和內部交易。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R0g?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R0g"/></p>
<p><em>此即時新聞警報由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前經過 MarketBeat 編輯團隊的審核。如對該故事有任何問題或意見，請發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1,000 美元在 Guardant Health 嗎？</h2>
<p>在考慮 Guardant Health 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前買入……而 Guardant Health 並不在名單上。</p>
<p>雖然 Guardant Health 目前在分析師中被評為買入，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

<p>Xponance Inc. 在最近的 13F 文件中報告，在第四季度收購了 8,534 股 Guardant Health, Inc.（納斯達克代碼：GH），價值約為 261,000 美元。其他對沖基金也增加了在 Guardant Health 的持倉。該股票開盤價為 43.14 美元，市值為 53.2 億美元，每股收益為負（0.90 美元）。分析師設定的目標價格範圍為 50 至 60 美元，平均評級為 “買入”，目標價格為 48.95 美元</p>

<p>Xponance Inc. bought a new position in Guardant Health, Inc. (NASDAQ:GH - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities &amp; Exchange Commission. The firm bought 8,534 shares of the company's stock, valued at approximately $261,000.</p>
<div class="lb-trans"><p>Xponance Inc. 在最近向證券交易委員會提交的 13F 文件中表示，在第四季度購買了 Guardant Health, Inc. (NASDAQ:GH - 免費報告) 的新頭寸。該公司購買了 8,534 股該公司的股票，價值約為 261,000 美元。</p>
</div><p>Get <strong>Guardant Health</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Guardant Health</strong> 警報：</p>
</div><ul>
<li>4 Healthcare Stocks With Massive Gains—and More to Come</li>
</ul>
<div class="lb-trans"><ul>
<li>4 只醫療保健股票大幅上漲——還有更多上漲空間</li>
</ul>
</div><p>Several other hedge funds also recently made changes to their positions in the company. R Squared Ltd bought a new position in Guardant Health during the 4th quarter valued at approximately $26,000. SBI Securities Co. Ltd. purchased a new position in shares of Guardant Health during the fourth quarter valued at approximately $43,000. Kimelman &amp; Baird LLC bought a new position in shares of Guardant Health during the fourth quarter valued at approximately $58,000. Jones Financial Companies Lllp lifted its stake in Guardant Health by 43.5% in the fourth quarter. Jones Financial Companies Lllp now owns 2,696 shares of the company's stock worth $82,000 after acquiring an additional 817 shares during the period. Finally, Van ECK Associates Corp boosted its holdings in Guardant Health by 47.4% in the fourth quarter. Van ECK Associates Corp now owns 2,887 shares of the company's stock valued at $88,000 after acquiring an additional 929 shares in the last quarter. 92.60% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>其他幾家對沖基金最近也對該公司的頭寸進行了調整。R Squared Ltd 在第四季度以約 26,000 美元的價格購買了 Guardant Health 的新頭寸。SBI Securities Co. Ltd. 在第四季度以約 43,000 美元的價格購買了 Guardant Health 的新頭寸。Kimelman &amp; Baird LLC 在第四季度以約 58,000 美元的價格購買了 Guardant Health 的新頭寸。Jones Financial Companies Lllp 在第四季度將其在 Guardant Health 的持股比例提高了 43.5%。Jones Financial Companies Lllp 目前擁有 2,696 股該公司的股票，價值 82,000 美元，此前在此期間又增持了 817 股。最後，Van ECK Associates Corp 在第四季度將其在 Guardant Health 的持股比例提高了 47.4%。Van ECK Associates Corp 目前擁有 2,887 股該公司的股票，價值 88,000 美元，此前在上個季度又增持了 929 股。92.60% 的股票由對沖基金和其他機構投資者持有。</p>
</div><h2>Guardant Health Price Performance</h2>
<div class="lb-trans"><h2>Guardant Health 價格表現</h2>
</div><p>Shares of Guardant Health stock opened at $43.14 on Friday. The stock has a market cap of $5.32 billion, a price-to-earnings ratio of -12.12 and a beta of 1.50. Guardant Health, Inc. has a 1 year low of $15.81 and a 1 year high of $50.89. The firm's 50-day moving average is $44.66 and its 200 day moving average is $34.24.</p>
<div class="lb-trans"><p>Guardant Health 股票週五開盤價為 43.14 美元。該公司的市值為 53.2 億美元，市盈率為 -12.12，貝塔值為 1.50。Guardant Health, Inc. 的一年低點為 15.81 美元，一年高點為 50.89 美元。該公司的 50 日移動平均線為 44.66 美元，200 日移動平均線為 34.24 美元。</p>
</div><ul>
<li>Deciphering Disruption: Inside Cathie Wood's Latest Plays</li>
</ul>
<div class="lb-trans"><ul>
<li>解讀顛覆：深入瞭解 Cathie Wood 的最新投資</li>
</ul>
</div><p>Guardant Health (NASDAQ:GH - Get Free Report) last issued its earnings results on Thursday, February 20th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.15). The firm had revenue of $201.81 million during the quarter, compared to the consensus estimate of $192.50 million. Guardant Health had a negative return on equity of 19,157.20% and a negative net margin of 59.05%. On average, equities analysts expect that Guardant Health, Inc. will post -2.9 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Guardant Health (NASDAQ:GH - 獲取免費報告) 最近於 2 月 20 日星期四發佈了其財報。該公司報告本季度每股收益為（$0.90），低於市場共識預期的（$0.75）$0.15。該公司本季度的收入為 2.0181 億美元，而市場共識預期為 1.9250 億美元。Guardant Health 的股本回報率為 -19,157.20%，淨利潤率為 -59.05%。分析師平均預計 Guardant Health, Inc. 本財年的每股收益為 -2.9。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>華爾街分析師預測增長</h2>
</div><p>Several brokerages have commented on GH. JPMorgan Chase &amp; Co. upped their price objective on shares of Guardant Health from $50.00 to $55.00 and gave the stock an &#34;overweight&#34; rating in a report on Friday, February 21st. Morgan Stanley increased their price target on shares of Guardant Health from $42.00 to $52.00 and gave the stock an &#34;overweight&#34; rating in a research note on Thursday, March 6th. Canaccord Genuity Group lifted their price objective on Guardant Health from $42.00 to $60.00 and gave the company a &#34;buy&#34; rating in a research report on Monday, February 24th. Stifel Nicolaus upped their target price on Guardant Health from $45.00 to $53.00 and gave the stock a &#34;buy&#34; rating in a report on Friday, February 21st. Finally, The Goldman Sachs Group raised their target price on Guardant Health from $49.00 to $56.00 and gave the company a &#34;buy&#34; rating in a research note on Friday, February 21st. Twenty investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Guardant Health presently has an average rating of &#34;Buy&#34; and an average target price of $48.95.</p>
<div class="lb-trans"><p>幾家券商對 GH 發表了評論。摩根大通將 Guardant Health 的目標價從 50.00 美元上調至 55.00 美元，並在 2 月 21 日的報告中給予該股票 “增持” 評級。摩根士丹利將 Guardant Health 的目標價從 42.00 美元上調至 52.00 美元，並在 3 月 6 日的研究報告中給予該股票 “增持” 評級。Canaccord Genuity Group 將 Guardant Health 的目標價從 42.00 美元上調至 60.00 美元，並在 2 月 24 日的研究報告中給予該公司 “買入” 評級。Stifel Nicolaus 將 Guardant Health 的目標價從 45.00 美元上調至 53.00 美元，並在 2 月 21 日的報告中給予該股票 “買入” 評級。最後，高盛集團將 Guardant Health 的目標價從 49.00 美元上調至 56.00 美元，並在 2 月 21 日的研究報告中給予該公司 “買入” 評級。20 位投資分析師對該股票給予了 “買入” 評級，根據 MarketBeat.com 的數據，Guardant Health 目前的平均評級為 “買入”，平均目標價為 48.95 美元。</p>
</div><ul>
<li>3 Fast-Growing Stocks Analysts See Doubling in Price</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只快速增長的股票分析師預計價格翻倍</li>
</ul>
</div><p><strong>Check Out Our Latest Stock Analysis on Guardant Health</strong></p>
<div class="lb-trans"><p><strong>查看我們對 Guardant Health 的最新股票分析</strong></p>
</div><h2>Guardant Health Company Profile</h2>
<div class="lb-trans"><h2>Guardant Health 公司簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.</p>
<div class="lb-trans"><p>Guardant Health, Inc. 是一家精準腫瘤學公司，在美國和國際上提供血液和組織檢測、數據集和分析。該公司提供 Guardant360；Guardant360 LDT；Guardant360 CDx 測試；Guardant360 反應測試；Guardant360 TissueNext 測試；GuardantINFINITY 測試；GuardantConnect，一種為臨牀和生物製藥客户設計的集成軟件解決方案，旨在將接受檢測的患者與具有潛在相關臨牀研究的可操作性改變相連接；GuardantOMNI 測試用於晚期癌症；以及 GuardantINFORM，一種用於各種生物標誌物驅動癌症的腫瘤演變和治療耐藥性的計算機研究平台。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精選故事</h2>
</div><ul>
<li>Five stocks we like better than Guardant Health</li>
<li>Comparing and Trading High PE Ratio Stocks</li>
<li>Why Dollar Tree’s Family Dollar Sale Could Spark a Comeback</li>
<li>Dividend King Proctor &amp; Gamble Is A Buy On Post-Earnings Weakness</li>
<li>JPMorgan: The 'NVIDIA of Banking' Poised for More Gains?</li>
<li>What is a buyback in stocks? A comprehensive guide for investors</li>
<li>Buy the Chewy Stock Reversal? Here’s Why Now Is the Time</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 Guardant Health</li>
<li>比較和交易高市盈率股票</li>
<li>為什麼 Dollar Tree 的 Family Dollar 出售可能會引發復甦</li>
<li>股息王寶潔在財報後疲軟時值得買入</li>
<li>摩根大通：銀行業的 “英偉達” 有望獲得更多收益？</li>
<li>股票回購是什麼？投資者的全面指南</li>
<li>買入 Chewy 股票反轉？這是現在的時機</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding GH?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Guardant Health, Inc. (NASDAQ:GH - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他對沖基金持有 GH 的股票嗎？</strong> 訪問 HoldingsChannel.com 獲取 Guardant Health, Inc. (NASDAQ:GH - 免費報告) 的最新 13F 文件和內部交易。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R0g" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=GH"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞警報由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前經過 MarketBeat 編輯團隊的審核。如對該故事有任何問題或意見，請發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Guardant Health Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Guardant Health 嗎？</h2>
</div><p>Before you consider Guardant Health, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Guardant Health 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Guardant Health wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前買入……而 Guardant Health 並不在名單上。</p>
</div><p>While Guardant Health currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Guardant Health 目前在分析師中被評為買入，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Xponance Inc. 收購了 8,534 股 Guardant Health, Inc.（NASDAQ: GH）的股票